BIVI Research Note — Clinical Optionality Meets Financing Pressure
BioVie’s Phase 2 optionality faces going-concern pressure, fragile liquidity and persistent weakness against the broader biotechnology group.
Research Notes
QQQ Research Note — A Crowded Earnings Test
QQQ remains above its long-term trend, but weak technology breadth, high Treasury yields and clustered mega-cap results demand operating confirmation.
SMH Research Note — Demand Meets a Fragile Tape
Semiconductor demand remains powerful, but concentration, rates and a weak intermediate trend leave SMH dependent on broader operating confirmation.
JPM Research Note — Strength Meets a Higher Bar
JPMorgan’s raised outlook and capital strength support the franchise case, while rates, credit and a record share price raise the evidence bar.
SPY Research Note — Trend Awaits Confirmation
SPY remains above its long-term trend but below its 50-day average as rates, breadth and a dense catalyst window test the next directional move.
VICI Research Note — Lease Strength Under Pressure
VICI’s long leases support visible cash flow, while rates, funding costs and tenant concentration determine whether its valuation discount is justified.
ECC Research Note — High Income Meets Distribution Risk
ECC’s estimated discount meets an August test of CLO equity cash flow, distribution durability, net asset value and unusually thin market liquidity.
WOLF Research Note — Survival Needs Operating Proof
Wolfspeed’s restructuring improved survival odds, but negative margins and weak utilization leave the operating recovery dependent on August evidence.
JQC Research Note — Income Meets Fragile Coverage
JQC’s discounted floating-rate income faces weak distribution coverage, heavy leverage and sensitivity to rates, credit and net asset value.
PLTR Research Note — Growth Meets a High Bar
PLTR’s commercial AI momentum faces a high August evidence bar as valuation sensitivity, insider supply and weak sector breadth complicate the setup.